Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Desline Barber
03.11.24 -- When In The Product's Life Cycle Does Continuous Manufacturing Make Sense?
Webinar: How To Identify And Quantify Adeno-Associated Virus Fill States Using Analytical Ultracentrifugation In addition to discussing how to implement Maruno's method of analysis to identify various fill states in AAV preparation, we’ll also cover the utilization and technical limitations of other techniques, such as analytical CsCl density gradient analysis and SEC-MALS, for characterization of AAV samples. Click here to learn more.
09.14.23 -- Geopartnering With Global Suppliers
Bio And The Business Of Aging With Life Biosciences' Jerry McLaughlin The fountain of youth might be a fantasy, but the science behind manipulating the biology of aging has become big business. But does the investment community understand and embrace the concept? Will regulatory agencies view aging as an indication that warrants therapeutic review? And how does a legitimate biopharma company separate itself from the consumer-packaged anti-aging and cosmetic procedures markets?
05.25.22 -- Reactor Tech's Influence On CDMO Selection
In Q2, 2020, ISR asked 76 biopharma respondents that outsource commercialized products how much influence the contract manufacturer’s reactor technology has on their choice of CDMO. The data show that reactor technology factors into the decision for almost all outsourcers of commercial biologics (95%). Two-thirds of respondents said reactor technology has a moderate or a lot of influence over the decision.
03.31.22 -- Biopharma Deal-Making In 2022: Key Trends
Article | By Desline Barber, IDT Biologika Lyophilization offers some alluring advantages in today’s complex market, but its challenges require innovation and expertise to surmount. White Paper | By Brian Anderson, AbbVie When executed properly, hot melt extrusion (HME) advances poorly soluble compounds in the development pipeline, without adding delays, cost, or significant post-processing activities, and can scale to commercial manufacturing.
03.28.22 -- Biopharma Deal-Making In 2022: Key Trends
Article | By Desline Barber, IDT Biologika Lyophilization offers some alluring advantages in today’s complex market, but its challenges require innovation and expertise to surmount. White Paper | By Brian Anderson, AbbVie When executed properly, hot melt extrusion (HME) advances poorly soluble compounds in the development pipeline, without adding delays, cost, or significant post-processing activities, and can scale to commercial manufacturing.
Lyophilization vs. Liquid Formulation: Why Lyo Offers Advantages For Drug Manufacturers
Article | March 8, 2022 By Desline Barber, Senior Scientist for Formulation Development, IDT Biologika As biologics such as vaccines, gene therapy and therapeutic proteins continue to advance to commercial viability, their complexities when compared to small molecules will necessitate new and novel approaches.
Lyophilization vs. Liquid Formulation: Why Lyo Offers Advantages For Drug Manufacturers
Article | March 8, 2022 By Desline Barber, Senior Scientist for Formulation Development, IDT Biologika As biologics such as vaccines, gene therapy and therapeutic proteins continue to advance to commercial viability, their complexities when compared to small molecules will necessitate new and novel approaches.
Lyophilization vs. Liquid Formulation: Why Lyo Offers Advantages For Drug Manufacturers
By Desline Barber, Senior Scientist for Formulation Development, IDT Biologika As biologics such as vaccines, gene therapy and therapeutic proteins continue to advance to commercial viability, their complexities when compared to small molecules will necessitate new and novel approaches.
Lyophilization vs. Liquid Formulation: Why Lyo Offers Advantages For Drug Manufacturers
By Desline Barber, Senior Scientist for Formulation Development, IDT Biologika As biologics such as vaccines, gene therapy and therapeutic proteins continue to advance to commercial viability, their complexities when compared to small molecules will necessitate new and novel approaches.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Desline
Contact Desline, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack